<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076579/results/search/test_trace/results.xml">
  <result pre="Infectious Disease Come Together: Review Reactivation of hepatitis B virus" exact="infection" post="in rheumatic diseases: risk and management considerations KoutsianasChristos[], [],"/>
  <result pre="morbidity and mortality. Because HBVr is easily preventable with appropriate" exact="screening" post="and monitoring strategies, and, when indicated, prophylactic antiviral treatment,"/>
  <result pre="advice on these issues. hepatitis B virus reactivation rheumatic disease" exact="screening" post="biologics DMARD immunosuppression Introduction Hepatitis B virus (HBV) infection"/>
  <result pre="disease screening biologics DMARD immunosuppression Introduction Hepatitis B virus (HBV)" exact="infection" post="still poses a significant worldwide morbidity and mortality burden,"/>
  <result pre="availability of an efficacious vaccine and antiviral treatment. The global" exact="prevalence" post="of chronic HBV infection has been recently estimated at"/>
  <result pre="vaccine and antiviral treatment. The global prevalence of chronic HBV" exact="infection" post="has been recently estimated at 3.61%,1 and, although it"/>
  <result pre="Europe and North America is likely to be changing the" exact="prevalence" post="and endemicity in these latter regions, which underlines the"/>
  <result pre="familiar with the disease. Most relevant studies suggest that the" exact="prevalence" post="of HBV in patients with rheumatic disease follows the"/>
  <result pre="disease follows the pattern of the general population. Chronic HBV" exact="infection" post="rates in rheumatoid arthritis (RA) and ankylosing spondylitis (AS)"/>
  <result pre="been estimated at 3.0% and 3.5%, respectively, whereas resolved HBV" exact="infection" post="rate ranges between 13% and 50%.3–5 HBV is a"/>
  <result pre="infants (&amp;gt;90%) and only &amp;lt;5% of adults develop chronic HBV" exact="infection" post="after exposure. Distinguishing between acute, chronic, past (resolved), and"/>
  <result pre="after exposure. Distinguishing between acute, chronic, past (resolved), and occult" exact="infection" post="lies in HBV serological markers and measurement of serum"/>
  <result pre="HBV serology (adapted from Koutsianas and colleagues5). Nomenclature for HBV" exact="infection" post="based on biochemistry, serology and viral load Acute HBV"/>
  <result pre="infection based on biochemistry, serology and viral load Acute HBV" exact="infection" post="Chronic HBV infection Past infection Chronic hepatitis Inactive carrier"/>
  <result pre="biochemistry, serology and viral load Acute HBV infection Chronic HBV" exact="infection" post="Past infection Chronic hepatitis Inactive carrier Resolved infection Occult"/>
  <result pre="and viral load Acute HBV infection Chronic HBV infection Past" exact="infection" post="Chronic hepatitis Inactive carrier Resolved infection Occult infection HBeAg"/>
  <result pre="Chronic HBV infection Past infection Chronic hepatitis Inactive carrier Resolved" exact="infection" post="Occult infection HBeAg (+) HBeAg (−) HBsAg + +"/>
  <result pre="infection Past infection Chronic hepatitis Inactive carrier Resolved infection Occult" exact="infection" post="HBeAg (+) HBeAg (−) HBsAg + + + +"/>
  <result pre="and 20,000 IU/mL cut-offs are arbitrary values deriving from the" exact="detection" post="limits of historical non-PCR methods of measurement. As HBV-related"/>
  <result pre="HBV-DNA, HBV-deoxyribonucleic acid; PCR, polymerase chain reaction. Figure 1. Serologic" exact="screening" post="for HBV and interpretation of results. anti-HBc, antibody against"/>
  <result pre="reactivation HBV reactivation (HBVr) is a well-recognized complication of immunosuppressive" exact="treatment" post="in cancer, rheumatic diseases, and organ transplantation.9 It typically"/>
  <result pre="organ transplantation.9 It typically occurs in patients with chronic HBV" exact="infection" post="[Hepatitis B surface Antigen (HBsAg) positive], but, less commonly,"/>
  <result pre="Antigen (HBsAg) positive], but, less commonly, it can complicate immunosuppressive" exact="treatment" post="in patients with resolved HBV infection [HBsAg negative/antibody against"/>
  <result pre="it can complicate immunosuppressive treatment in patients with resolved HBV" exact="infection" post="[HBsAg negative/antibody against Hepatitis B core antigen (anti-HBc) positive]."/>
  <result pre="a rise in serum HBV-DNA compared with baseline levels or" exact="detection" post="of HBV DNA if undetectable at baseline, or reverse"/>
  <result pre="diseases, rheumatologists should be aware of the potential risk, the" exact="screening" post="recommendations, and management options for prophylaxis and monitoring for"/>
  <result pre="of therapy longer (years). In a recent meta-analysis for the" exact="prevalence" post="of HBVr in rheumatic diseases being treated with conventional"/>
  <result pre="serological status and the type and duration of the immunosuppressive" exact="treatment" post="used. The American Gastroenterological Association (AGA) classified HBVr risk"/>
  <result pre="and management Glucocorticoids Glucocorticoid (GC) use in patients with HBV" exact="infection" post="was known to relate to HBVr as early as"/>
  <result pre="evidence that even short courses of more than moderate-dose GC" exact="treatment" post="in chronic HBV infection can lead to HBVr.17,20–22 Chemotherapy"/>
  <result pre="courses of more than moderate-dose GC treatment in chronic HBV" exact="infection" post="can lead to HBVr.17,20–22 Chemotherapy for chronically HBV-infected patients"/>
  <result pre="in medium to high (&amp;gt;20 mg/day) doses.24 Patients with chronic HBV" exact="infection" post="and rheumatic diseases are also at risk for HBVr"/>
  <result pre="at 10 years. GC peak daily dose &amp;gt;20 mg prednisolone equivalents and" exact="treatment" post="duration for &amp;gt;4 weeks were independent risk factors for a"/>
  <result pre="not identify studies from geographical areas with less prevalent HBV" exact="infection" post="to confirm this relatively high HBVr rate. GC use"/>
  <result pre="suggests that daily doses of GCs &amp;gt;20 mg prednisolone equivalents for" exact="treatment" post="durations &amp;gt;4 weeks should be considered as having at least"/>
  <result pre="and more rarely with chronic (fibrosis) hepatotoxicity. With appropriate pre-treatment" exact="screening" post="and regular monitoring, these events are rarely seen today."/>
  <result pre="unclear.36 Similarly, among patients with rheumatic disease and resolved HBV" exact="infection" post="taking part in a large prospective multicenter study, use"/>
  <result pre="the other non-biologic agents should be considered as low risk" exact="treatment" post="for HBVr in patients with both chronic and resolved"/>
  <result pre="retrospective study of SLE patients with chronic or resolved HBV" exact="infection" post="from Taiwan, MMF was not found to be among"/>
  <result pre="Whereas things are more-or-less clear-cut with patients with chronic HBV" exact="infection" post="being candidates for prophylactic antiviral treatment, data on the"/>
  <result pre="data on the management of rheumatic patients with resolved HBV" exact="infection" post="planned to be treated with CYC-containing regimens remain scarce."/>
  <result pre="a total of 138 HBV-infected patients, most with chronic HBV" exact="infection" post="(n = 99, 72%); among them, 11 (8%) had been treated"/>
  <result pre="resolved (n = 157) HBV infection.43 Among 34 patients with chronic HBV" exact="infection" post="not on antiviral prophylaxis, HBVr occurred in 15 (44%),"/>
  <result pre="(44%), whereas in contrast, only 3 (1.9%) patients with resolved" exact="infection" post="experienced HBsAg seroreversion. However, in multivariate analysis, CYC was"/>
  <result pre="patients, while the respective risk in patients with resolved HBV" exact="infection" post="is rather low. Prophylactic antiviral prophylaxis should be used"/>
  <result pre="not support universal antiviral protection for patients with resolved HBV" exact="infection" post="prior to induction of remission with CYC-containing regimens. Biologic"/>
  <result pre="Biologic disease-modifying antirheumatic drugs TNFi TNF inhibition has revolutionized the" exact="treatment" post="of several rheumatic diseases since the late 1990s. When"/>
  <result pre="may favor HBVr.46 The risk of HBVr in chronic HBV" exact="infection" post="patients receiving TNFi has been identified and is well"/>
  <result pre="appeared within the first year of TNFi treatment. Nucleos(t)ide analogue" exact="treatment" post="at the time of HBVr usually results in prompt"/>
  <result pre="cases of severe liver injury and hepatic failure despite antiviral" exact="treatment" post="at the time of HBVr. It has been also"/>
  <result pre="time of HBVr. It has been also shown that antiviral" exact="treatment" post="is efficacious in preventing HBVr as supported by the"/>
  <result pre="contrary, it seems that the HBVr risk in resolved HBV" exact="infection" post="patients treated with TNF inhibitors is significantly lower.47–49,52,55,56 In"/>
  <result pre="no cases of HBVr were found among 146 resolved HBV" exact="infection" post="patients treated with TNFi for a mean period of"/>
  <result pre="could be due to different states of the underlying HBV" exact="infection" post="(occult versus resolved) or due to different HBV strains."/>
  <result pre="of these data, TNF inhibition in patients with chronic HBV" exact="infection" post="(HBsAg+) carries a significant HBVr risk and it is"/>
  <result pre="into the benefit of using antiviral prophylaxis in chronic HBV" exact="infection" post="patients receiving RTX-containing regimens, the HBVr rate was as"/>
  <result pre="robust data to support that RTX use in chronic HBV" exact="infection" post="is associated with very high HBVr rates (30–60%)17,33 and"/>
  <result pre="controversy, the authors believe that in patients with resolved HBV" exact="infection" post="and undetectable baseline serum HBV-DNA, serial monitoring of aminotransferases,"/>
  <result pre="The HBVr risk for chronically infected HBV patients on ABA" exact="treatment" post="has been explored only in small retrospective studies. In"/>
  <result pre="a recently studied Japanese cohort were reported on resolved HBV" exact="infection" post="patients treated with ABA (total n = 29, 10.3%).81 In another"/>
  <result pre="10.3%).81 In another study, among 24 patients with resolved HBV" exact="infection" post="on ABA treatment, three cases of HBVr were reported"/>
  <result pre="no HBVr cases were observed among the nine resolved HBV" exact="infection" post="patients treated with ABA in the prospective trial by"/>
  <result pre="ABA since its approval, cases of HBVr in resolved HBV" exact="infection" post="appear to be rare, especially in geographical areas with"/>
  <result pre="in chronic HBV infection, but close monitoring in resolved HBV" exact="infection" post="seems to be a safe alternative. Interleukin-6 inhibitors Inhibition"/>
  <result pre="interleukin (IL)-6 provides a new mechanism of action for the" exact="treatment" post="of rheumatic disease, and two agents have been approved"/>
  <result pre="can occur with TCZ therapy in patients with chronic HBV" exact="infection" post="without antiviral prophylaxis.25,83–86 In all published data, the use"/>
  <result pre="Interleukin-17 inhibitors IL-17 inhibitors have recently been approved for the" exact="treatment" post="of psoriasis, psoriatic arthritis, and axial spondyloarthropathy. As patients"/>
  <result pre="psoriasis, psoriatic arthritis, and axial spondyloarthropathy. As patients with HBV" exact="infection" post="were excluded from the initial controlled clinical trials for"/>
  <result pre="chronic or resolved HBV infection. Among those with chronic HBV" exact="infection" post="who did not receive antiviral prophylaxis, 27% (6/22) developed"/>
  <result pre="respective rate of virological HBVr in those with resolved HBV" exact="infection" post="was 4% (1/24).95 In the absence of solid data"/>
  <result pre="Taiwanese retrospective cohort,96 11 chronic HBV and 3 resolved HBV" exact="infection" post="patients with psoriasis received ustekinumab. HBVr was observed in"/>
  <result pre="HBVr was observed in two of the seven chronic HBV" exact="infection" post="patients who did not receive antiviral prophylaxis; in both"/>
  <result pre="as guselkumab, risankizumab, and tildrakizumab have been approved for the" exact="treatment" post="of psoriasis and are currently under investigation for psoriatic"/>
  <result pre="literature data on their use in the setting of HBV" exact="infection" post="are available and, thus, no relevant recommendations exist. csDMARD"/>
  <result pre="of whether csDMARD and biologic disease-modifying antirheumatic drug (bDMARD) combination" exact="treatment" post="in rheumatic patients carries higher risk for HBVr compared"/>
  <result pre="agents that were recently introduced into daily clinical practice for" exact="treatment" post="of RA, psoriatic arthritis, and ulcerative colitis. JAK inhibitors"/>
  <result pre="the effect of baricitinib in RA patients with past HBV" exact="infection" post="in a post hoc analysis of baricitinib clinical trials.100"/>
  <result pre="In a significant proportion (73–84%) of patients with resolved HBV" exact="infection" post="(HBsAg negative/anti-HBc positive), circulating anti-HBs antibodies can be detected"/>
  <result pre="data have been reported in rheumatic patients with resolved HBV" exact="infection" post="treated with different immunosuppressives and prospective studies support the"/>
  <result pre="Among 1042 Japanese patients with rheumatic diseases and resolved HBV" exact="infection" post="who received both conventional and biological treatments, HBVr incidence"/>
  <result pre="anti-HBs titres below the median (71.4 IU/mL) and the cut-off for" exact="detection" post="(&amp;lt;10 IU/mL), respectively.37 Finally, a meta-analysis of HBVr in studies"/>
  <result pre="meta-analysis of HBVr in studies of patients with resolved HBV" exact="infection" post="from all medical fields showed that the total pooled"/>
  <result pre="measurements replacing monitoring with serum HBV DNA. Recommendations for HBVr" exact="screening" post="and management Screening The valued benefit of screening for"/>
  <result pre="for HBVr screening and management Screening The valued benefit of" exact="screening" post="for HBV infection prior commencing immunosuppressive treatment has been"/>
  <result pre="and management Screening The valued benefit of screening for HBV" exact="infection" post="prior commencing immunosuppressive treatment has been established in several"/>
  <result pre="valued benefit of screening for HBV infection prior commencing immunosuppressive" exact="treatment" post="has been established in several medical society guidelines. Increasing"/>
  <result pre="80% of HBVr could be preventable.45 The cost-effectiveness of HBV" exact="screening" post="has been studied in several studies from the hematology-oncology"/>
  <result pre="in several studies from the hematology-oncology field, where a universal" exact="screening" post="strategy was found to be cost-effective in studies with"/>
  <result pre="or solid malignancies,111 and it seemed to improve cost-effectiveness by" exact="screening" post="high-risk patients only. We were unable to identify similar"/>
  <result pre="only. We were unable to identify similar studies assessing HBV" exact="screening" post="cost-effectiveness in rheumatic patients prior to immunosuppression. Given the"/>
  <result pre="risk of HBVr associated with the immunosuppressive potency of the" exact="treatment" post="used, we recommend universal screening in patients scheduled to"/>
  <result pre="the immunosuppressive potency of the treatment used, we recommend universal" exact="screening" post="in patients scheduled to start biologic and targeted synthetic"/>
  <result pre="also of concern (especially for methotrexate and leflunomide) and, thus," exact="screening" post="should be performed in all patients.5 A suggested algorithm"/>
  <result pre="should be performed in all patients.5 A suggested algorithm for" exact="screening" post="and interpretation of results is presented in Figure 1."/>
  <result pre="The authors support the inclusion of anti-HBs in the serological" exact="screening" post="markers (HBsAg, anti-HBc) as suggested by recent American Association"/>
  <result pre="initial or booster vaccination, but also cases of occult HBV" exact="infection" post="in anti-HBs positive patients that have not been vaccinated"/>
  <result pre="however, these responses could be attenuated in older persons.112,113 A" exact="screening" post="algorithm that includes HBsAg, anti-HBc, and anti-HBs (Figure 1)"/>
  <result pre="infection), but also on the HBVr potential of the immunosuppressive" exact="treatment" post="used (Table 4). Figure 2. Suggested algorithm for the"/>
  <result pre="the oncology field, in the setting of rheumatic disease, immunosuppressive" exact="treatment" post="is usually used for prolonged periods of time, even"/>
  <result pre="cessation of prophylaxis, the suggestion is to continue with prophylactic" exact="treatment" post="for at least 6 months after the end of"/>
  <result pre="for at least 6 months after the end of antirheumatic" exact="treatment" post="(12 months if that treatment is RTX). Reaching the"/>
  <result pre="after the end of antirheumatic treatment (12 months if that" exact="treatment" post="is RTX). Reaching the therapeutic endpoint as per hepatology"/>
  <result pre="if this is B-cell depleting treatment.113 Patients with chronic HBV" exact="infection" post="(HBsAg+) form the group with the highest HBVr risk."/>
  <result pre="taken after consulting a specialist with experience in treating HBV" exact="infection" post="(gastroenterologist, hepatologist, infectious disease specialist, etc.). In chronic active"/>
  <result pre="issue of antiviral prophylaxis in rheumatic patients with resolved HBV" exact="infection" post="(HBsAg+, Anti-HBc–) treated with immunosuppressives remains currently the most"/>
  <result pre="For example, a recent meta-analysis of HBVr in resolved HBV" exact="infection" post="patients found that the pooled HBVr rates were much"/>
  <result pre="of RTX in large populations of rheumatic patients with resolved" exact="infection" post="(ranging from 5% to 50% in the general population),"/>
  <result pre="low and prophylactic antiviral therapy is not required.6 Nevertheless, baseline" exact="screening" post="with HBV DNA and close monitoring with ALT, HBsAg,"/>
  <result pre="described above. Summary In patients with rheumatic disease under immunosuppressive" exact="treatment" post="and HBV infection, HBVr is a potentially severe and"/>
  <result pre="patient and on the therapeutic agent used, with the highest" exact="prevalence" post="connected to biologic and targeted synthetic drugs, especially those"/>
  <result pre="Dimitrios Vassilopoulos https://orcid.org/0000-0003-2288-3863 References References 1SchweitzerAHornJMikolajczykRT, et al.Estimations of worldwide" exact="prevalence" post="of chronic hepatitis B virus infection: a systematic review"/>
  <result pre="der HeijdeD, et al.Prevalence of comorbidities and evaluation of their" exact="screening" post="in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study."/>
  <result pre="Rheum Dis2016; 75: 1016–1023.26489703 5KoutsianasCThomasKVassilopoulosDHepatitis B reactivation in rheumatic diseases:" exact="screening" post="and prevention. Rheum Dis Clin North Am2017; 43: 133–149.27890170"/>
  <result pre="Hepatology2009; 49: S156–S165.19399803 10TerraultNALokASFMcMahonBJ, et al.Update on prevention, diagnosis, and" exact="treatment" post="of chronic hepatitis B: AASLD 2018 hepatitis B guidance."/>
  <result pre="436–443.29223453 17PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological Association Institute technical review on prevention and" exact="treatment" post="of hepatitis b virus reactivation during immunosuppressive drug therapy."/>
  <result pre="of interferon alfa-2b alone and after prednisone withdrawal for the" exact="treatment" post="of chronic hepatitis B. The Hepatitis Interventional Therapy Group."/>
  <result pre="B. Liver Int2019; 39: 271–279.30179316 27Braun-MoscoviciYBraunMSaadiT, et al.Safety of corticosteroid" exact="treatment" post="in rheumatologic patients with markers of hepatitis B viral"/>
  <result pre="viral infection. J Clin Rheumatol2016; 22: 364–368.27660934 28LinY-CLeeS-WYehH-Z, et al.The" exact="prevalence" post="and risk factors of hepatitis B flares in chronic"/>
  <result pre="et al.Risk of hepatitis B surface antigen seroreversion after corticosteroid" exact="treatment" post="in patients with previous hepatitis B virus exposure. J"/>
  <result pre="al.Incidence of hepatitis B virus reactivation in patients with resolved" exact="infection" post="on immunosuppressive therapy for rheumatic disease: a multicentre, prospective,"/>
  <result pre="Clin Rheumatol2010; 29: 1021–1029.20556450 47VassilopoulosDApostolopoulouAHadziyannisE, et al.Long-term safety of anti-TNF" exact="treatment" post="in patients with rheumatic diseases and chronic or resolved"/>
  <result pre="Rheumatol2009; 36: 1188–1194.19447932 51ChungSKimJKParkM-C, et al.Reactivation of hepatitis B viral" exact="infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy."/>
  <result pre="Clin Rheumatol2014; 33: 119–123.24077913 55MoriS, et al.Past hepatitis B virus" exact="infection" post="in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying"/>
  <result pre="312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic hepatitis B virus" exact="infection" post="following rituximab administration for rheumatoid arthritis. Rheumatol Int2011; 31:"/>
  <result pre="67HuiC-KCheungWWWZhangH-Y, et al.Kinetics and risk of de novo hepatitis B" exact="infection" post="in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology2006; 131: 59–68.16831590"/>
  <result pre="Care Res2016; 68: 738–743. 79FanouriakisAVassilopoulosDRepaA, et al.Hepatitis B reactivation following" exact="treatment" post="with abatacept in a patient with past hepatitis B"/>
  <result pre="80GermanidisGHytiroglouPZakalkaM, et al.Reactivation of occult hepatitis B virus infection, following" exact="treatment" post="of refractory rheumatoid arthritis with abatacept. J Hepatol2012; 56:"/>
  <result pre="hepatitis B. Mod Rheumatol2011; 21: 701–705.21626075 85KishidaDOkudaYOnishiM, et al.Successful tocilizumab" exact="treatment" post="in a patient with adult-onset Still’s disease complicated by"/>
  <result pre="complicated psoriasis and psoriatic arthritis patient with hepatitis B virus" exact="infection" post="and end-stage kidney disease on hemodialysis. JAAD Case Reports2019;"/>
  <result pre="Reports2019; 5: 150–152.30733983 95ChiuHHuiRHuangY, et al.Safety Profile of secukinumab in" exact="treatment" post="of patients with psoriasis and concurrent hepatitis B or"/>
  <result pre="829–834.29972221 96ChiuH-YChenC-HWuM-S, et al.The safety profile of ustekinumab in the" exact="treatment" post="of patients with psoriasis and concurrent hepatitis B or"/>
  <result pre="Discov2017; 17: 78. 99ChenY-MHuangW-NWuY-D, et al.Reactivation of hepatitis B virus" exact="infection" post="in patients with rheumatoid arthritis receiving tofacitinib: a real-world"/>
  <result pre="102De PaschaleMMancoMTBelvisiL, et al.Prevalence of markers of hepatitis B virus" exact="infection" post="or vaccination in HBsAg-negative subjects. Blood Transfus2012; 10: 344–350.22682333"/>
  <result pre="surface antibody in hepatitis B reactivation in patients with resolved" exact="infection" post="and hematologic malignancy: a meta-analysis. Hepatology2017; 66: 379–388.28128861 106TienY-CHsueY-THungM-H,"/>
  <result pre="The PRESCRIB Project. Hepatology2014; 106–113.24585503 109KonijetiGGGrandheSKonermanM, et al.Cost-effectiveness analysis of" exact="screening" post="for hepatitis B virus infection in patients with solid"/>
  <result pre="109KonijetiGGGrandheSKonermanM, et al.Cost-effectiveness analysis of screening for hepatitis B virus" exact="infection" post="in patients with solid tumors before initiating chemotherapy. Clin"/>
  <result pre="DOI: 10.1016/j.cgh.2019.10.039. 110CrespoJEstebanRTorresC, et al.Cost-effectiveness of a hepatitis B virus" exact="screening" post="strategy to prevent reactivation in patients with hematologic neoplasms."/>
  <result pre="109: 619–626.28648087 111HwangJPHuangDVierlingJM, et al.Cost-effectiveness analysis of hepatitis B virus" exact="screening" post="and management in patients with hematologic or solid malignancies"/>
  <result pre="comprehensive immunization strategy to eliminate transmission of hepatitis B virus" exact="infection" post="in the United States: recommendations of the Advisory Committee"/>
 </snippets>
</snippetsTree>
